ERBB2 and breast cancer: Given that major advances in treatment have largely been seen in the hormone receptor- and HER2-positive clinical subtypes, it is not surprising that TNBC has the poorest prognosis of all BC, contributing to worse outcomes in Black women simply due to the frequency of this subtype39.